Sensors for Medicine and Science (Germantown, MD) a commercial-stage device company focused on implantable, long- term continuous glucose monitoring, closed a $54.1M million in Series D financing. Participants include Delphi Ventures, New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

Tesaro (Boston, MA) a clinical-stage biopharmaceutical focused on chemotherapy induced nausea and non-small cell lung cancer, closed a $101M Series B financing. Participants include New Enterprise Associates, InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Capital Management and Leerink Swann.

VertiFlex (San Clamente, CA) a clinical-stage medical device company focused on percutaneous and motion preserving spinal surgery technologies, closed a $14M Series E financing. Participants include New Enterprise Associates, Aberdare Ventures, Alta Partners and Thomas, McNerney & Partners.

BridgePoint Medical (Minneapolis, MN) a clinical-stage medical device company focused on interventional cardiology for access to and treatment of chronic total occlusions, closed a $9.1M Series C financing. Participants include New Enterprise Associates, Polaris Venture Partners and Foundation Medical Partners.

Omthera Pharmaceuticals (Bedminster, NJ) a clinical-stage specialty biopharma company focused on an Omega-3 fatty acid containing DHA and EPA as a therapy for dyslipidemia, closed a $33.9M Series B financing. Participants include New Enterprise Associates and Sofinnova Ventures.

Ulthera (Mesa, AZ) a commercial-stage medical device company focused on ultrasound technology in the aesthetics market, closed a $10.5M Series C financing. Participants include New Enterprise Associates and Apposite Capital.

23andMe (Mountain View, CA) a commercial-stage personalized genomics company focused on aiding individuals with DNA analysis technologies and web-based interactive tools, closed a $22M Series C financing. Participants include Johnson & Johnson Development Corp, New Enterprise Associates, Google Ventures and MPM Capital.

Cardioxyl Pharmaceuticals (Chapel Hill, NC) a clinical-stage small molecule company focused on acute decompensated heart failure, closed a $15M Series C financing. Participants include Aurora Funds and New Enterprise Associates.

Rhythm Pharmaceuticals (Boston, MA) a clinical-stage small peptide company focused on diabetes, obesity and GI disorders, closed a $19M Series A financing, bringing the total round to $40M. Participants include MPM Capital, New Enterprise Associates and Third Rock Ventures.

Trevena (Berwyn, PA) a clinical-stage small molecule company focused on G-protein coupled receptor targeting for heart failure and pain, closed a $35M Series B funding from existing investors. Participants include Polaris Venture Partners, New Enterprise Associates, Alta Partners, Healthcare Ventures and Yasuda Enterprise Development Company.

TriVascular (Santa Rosa, CA) a commercial-stage medical device company focused on endovascular repair devices for the treatment of abdominal aortic aneurysms, closed a $60M Series C financing. Participants include Pinnacle Ventures, New Enterprise Associates, Delphi Ventures, MPM Capital and Kearny Venture Partners.

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

Predictive Biosciences (Lexington, MA) a commercial-stage molecular diagnostic company focused on oncology assays, closed a $25M Series C financing. Participants ProQuest Investments, Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates.